PASADENA, Calif.--(BUSINESS WIRE)--Calando Pharmaceuticals, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that it has initiated a Phase II clinical trial in the United States evaluating the safety and efficacy of its drug candidate, IT-101 in patients with platinum-sensitive ovarian cancer. The study is open for enrollment.
